SCHEMBL5715397

SCHEMBL5715397

O=C(Oc1ccc(Cc2ccc(C(F)(F)F)cn2)cc1)N1CCN(Cc2ccccn2)CC1

nearest known ligand 0.79

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.53
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
LIPE Q05469 8/20 0.48
TRPV1 Q8NER1 1/20 0.48
TRPA1 O75762 1/20 0.47
BCHE P06276 1/20 0.47
PPARG P37231 1/20 0.45
PPARD Q03181 1/20 0.45
PPARA Q07869 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714274 0.92 TRPV1 (0.54) SCN9AKDM4EALDH1A1TRPV1TRPA1
SCHEMBL5714135 0.91 TP53 (0.49) SCN9ALIPETRPV1TRPA1BCHE
SCHEMBL5715540 0.90 LIPE (0.46) SCN9ALIPETRPV1TRPA1BCHE
SCHEMBL5714719 0.89 LIPE (0.48) SCN9ALIPETRPV1TRPA1BCHE
SCHEMBL5714347 0.88 ALDH1A1 (0.60) KDM4EALDH1A1
SCHEMBL5714399 0.88 LIPE (0.47) SCN9ALIPETRPV1TRPA1BCHE
SCHEMBL5715259 0.87 LIPE (0.48) LIPETRPV1BCHEPPARGPPARD
SCHEMBL5714246 0.87 LIPE (0.46) SCN9ALIPETRPV1BCHEPPARG
SCHEMBL5715001 0.86 HIF1A (0.52) KDM4EALDH1A1LIPETRPV1TRPA1
SCHEMBL5649791 0.86 SCN9A (0.67) SCN9AKDM4EALDH1A1LIPEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL SCN9A 3933/4885KDM4E 1090/4885ALDH1A1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.